FDA adds boxed warning of increased severe hypocalcemia risk for denosumab
The FDA has added a boxed warning to denosumab (Prolia, Amgen) due to an increased risk for severe hypocalcemia for people with advanced chronic kidney disease (CKD), particularly those on dialysis. A study published in JAMA found that women on dialysis who initiated treatment with denosumab had a higher risk for severe hypocalcemia compared to…